Hepatitis C News

According to HHS, many of the more than 3.2 million people in the United States with hepatitis B or C are not aware of their infection, raising their risk for severe complications or death and risking further spread of the viruses.

Results from a systematic review and meta-analysis demonstrated greater risk for hepatitis C virus and HIV infection among women and younger people who inject drugs, according to data reported in The Lancet Gastroenterology & Hepatology.

Hepatitis C virus among the U.S. obstetric population rose nearly 10-fold over 20 years, which might reflect an increase in screening or prevalence, according to researchers.

A call back system in Taiwan helped retrieve patients with chronic hepatitis C virus infection who were lost to follow-up and has the potential to boost micro-elimination efforts, according to research in BMC Gastroenterology.

Testing for HIV, hepatitis B, and hepatitis C increased among U.S. Medicaid enrollees initiating treatment for opioid use disorder. However, a recent study showed approximately three-quarters of enrollees were not tested for each condition.

WASHINGTON — Active IV or prescription drug use did not affect attainment of sustained virologic response when treatment adherence for hepatitis C virus was already variable, according to a poster presented at The Liver Meeting.

Direct-acting antiviral treatment significantly lowered the risk for mortality and liver and non-liver outcomes in patients with chronic hepatitis C virus infection, regardless of disease stage, researchers reported.

WASHINGTON — In this video, Norah Terrault, MD, MPG, FAASLD, chief of gastroenterology and liver diseases at the University of Southern California Keck School of Medicine, discusses a national strategy to eliminate hepatitis C virus.

WASHINGTON — A leading expert in hepatology called for fellow specialists to embrace a role of education, advocacy and support as part of a proposed national hepatitis C virus elimination program presented during The Liver Meeting.

WASHINGTON — Vosevi, a triple-combination therapy for chronic hepatitis C virus infection, was effective when used as a rescue treatment in patients who did not achieve sustained virologic response with direct-acting antiviral agents.